Paracetamol

The effectiveness of the combination of 3-BP with paracetamol was dramatically demonstrated in the metastatic melanoma patient (1). The patient had terminal stage metastatic cancer with extremely severe tumor burden. His life expectancy from the start of 3-BP was less than one month. Eight treatments of IV 3-BP doses ranging from 1 - 2.2 mg/kg given over a period of 3 weeks had significant, though not profound effect on his tumor burden as measured by LDH (see Figure 4). However, two combination treatments of 3-BP and paracetamol resulted in a metabolic cure of his cancer. The patient soon after succumbed to respiratory distress caused by a massive pulmonary tumor obstructing his airway. The article notes, however, that his tumor was no longer metabolically active.

Paracetamol profoundly enhances the effectiveness of 3-BP. The concern with using it would be the very real danger of inducing tumor lysis syndrome (TLS). Yet, TLS is a medically preventable andmanageable response to anti-cancer treatment. Combining 3-BP with paracetamol might lower any risk posed by 3-BP, as the required treatment dose of 3-BP could be reduced considerably.

(1)Chin J Cancer. 2014 Jul;33(7):356-64. doi: 10.5732/cjc.013.10111. Epub 2014 Mar 14.

Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate : a concise literature review and case study. http://www.ncbi.nlm.nih.gov/pubmed/24636230   full text at  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110469/